Takeda Pharmaceutical Company Limited (TKPHF)
OTCMKTS
· Delayed Price · Currency is USD
32.13
0.00 (0.00%)
Apr 24, 2025, 4:00 PM EDT
Takeda Pharmaceutical Company Employees
Takeda Pharmaceutical Company had 49,281 employees as of March 31, 2024. The number of employees increased by 186 or 0.38% compared to the previous year.
Employees
49,281
Change (1Y)
186
Growth (1Y)
0.38%
Revenue / Employee
$590,997
Profits / Employee
$26,854
Market Cap
45.09B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 3,116 |
| Glass House Brands | 374 |
| Elite Pharmaceuticals | 64 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 9 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
| Longduoduo Company | 49 |
Takeda Pharmaceutical Company News
- 5 days ago - How Takeda's CEO transformed the company into a global pharma powerhouse - CNBC
- 19 days ago - BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 - Accesswire
- 26 days ago - Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns - Seeking Alpha
- 6 weeks ago - Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds - Seeking Alpha
- 7 weeks ago - Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer - Benzinga
- 7 weeks ago - Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera - Business Wire
- 2 months ago - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) - Benzinga
- 2 months ago - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) - PRNewsWire